Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jul 31;14(7):1183-1186.
doi: 10.21037/gs-2025-178. Epub 2025 Jul 28.

Axillary dissection should not be performed in breast cancer patients with limited nodal disease to determine abemaciclib candidacy

Brenton Halsey  1 , Elizabeth McAuley Fish  1 , Walker Lyons  1 , Melissa McShane  1 , Austin D Williams  1
Affiliations
Editorial

Axillary dissection should not be performed in breast cancer patients with limited nodal disease to determine abemaciclib candidacy

Brenton Halsey et al. Gland Surg. .
No abstract available

Keywords: NATALEE; SENOMAC; axillary dissection; cyclin-dependent kinase 4/6 inhibitors (CDK4/6 inhibitors); monarchE.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://gs.amegroups.com/article/view/10.21037/gs-2025-178/coif). M.M. receives consulting fees from AstraZeneca. A.W. receives consulting fees from Elucent Medical. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Johnston SRD, Toi M, O'Shaughnessy J, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol 2023;24:77-90. 10.1016/S1470-2045(22)00694-5 - DOI - PMC - PubMed
    1. Rastogi P, O'Shaughnessy J, Martin M, et al. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. J Clin Oncol 2024;42:987-93. Erratum in: J Clin Oncol 2024;42:2111. Erratum in: J Clin Oncol 2025;43:113. 10.1200/JCO.23.01994 - DOI - PMC - PubMed
    1. Giuliano AE, Ballman KV, McCall L, et al. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 2017;318:918-26. 10.1001/jama.2017.11470 - DOI - PMC - PubMed
    1. Bartels SAL, Donker M, Poncet C, et al. Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial. J Clin Oncol 2023;41:2159-65. 10.1200/JCO.22.01565 - DOI - PubMed
    1. Williams AD, Ruth K, Shaikh SS, et al. Should patients with hormone receptor-positive, HER2-negative breast cancer and one or two positive sentinel nodes undergo axillary dissection to determine candidacy for adjuvant abemaciclib? Cancer 2024;130:1052-60. 10.1002/cncr.35136 - DOI - PMC - PubMed

LinkOut - more resources